Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of pediatric ritlecitinib formulations in healthy adults
NCT05040295Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ritlecitinib tosilate in alopecia areata (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time at 24 hours and Maximum Plasma Concentration at 24 hours. Started Sep 2021; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05040295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05040295.